PVRIG (Poliovirus Receptor–Related Immunoglobulin domain–containing protein) is an emerging immune checkpoint receptor that plays a key role in regulating T-cell and natural killer (NK) cell activity within the tumor microenvironment. By interacting primarily with its ligand CD112, PVRIG contributes to immune suppression that can limit effective anti-tumor responses. Its importance in drug discovery stems from the growing recognition that targeting alternative immune checkpoints beyond PD-1 and CTLA-4 may overcome resistance to existing immunotherapies. Inhibiting PVRIG has the potential to restore immune cell function, enhance anti-cancer immunity, and synergize with other checkpoint inhibitors, making it a promising target for next-generation immuno-oncology drugs.
VisitAurora Biolabs
7270 Trade Street, Suite 103
San Diego, CA 92121, USA
